BRIEF—Pfizer adds to Vyndaqel data with RWE

US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure.

These results show the survival rates among patients with transthyretin cardiac amyloidosis (ATTR-CM) treated or untreated with Vyndaqel (tafamidis).

The pivotal Phase III ATTR-ACT study demonstrated that tafamidis improved survival and reduced the risk of cardiovascular-related hospitalization compared with placebo in patients with ATTR-CM. 

In this real-world cohort from the THAOS study, survival rates were numerically higher than reported in the ATTR-ACT trial, and no new safety signals were identified. 

These results from THAOS add further support for the effectiveness of tafamidis for patients with ATTR-CM, according to Pfizer.